Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary nervous system lymphoma.

Scott R Plotkin1, Tracy T Batchelor

  • 1Brain Tumor Center, Cox 315, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA. tbatchelor@partners.org

Current Treatment Options in Oncology
|October 24, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and Initial Validation of the Quality of life Evaluation in <i>NF2</i> -related Schwannomatosis Trials (QUEST) Assessment.

medRxiv : the preprint server for health sciences·2026
Same author

IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma.

Future oncology (London, England)·2026
Same author

Reliability of a modified mini balance evaluation systems test (Mini-BESTest) in NF2-related schwannomatosis.

Gait & posture·2026
Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study.

Blood·2026
Same author

Deciphering and Targeting the Schwannoma-Neuron-Macrophage Crosstalk for the Treatment of Schwannomatosis and Associated Pain.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Primary nervous system lymphoma (PNSL) treatment has shifted to methotrexate-based chemotherapy, improving outcomes but rarely achieving cures. Research focuses on new agents to overcome challenges like the blood-brain barrier and neurotoxicity.

Area of Science:

  • Neuro-oncology
  • Hematology
  • Clinical Trials

Background:

  • Primary nervous system lymphoma (PNSL) is a rare non-Hodgkin's lymphoma affecting the brain, spinal cord, and meninges.
  • Historically treated with whole brain radiation therapy, PNSL management faces high relapse rates and significant neurotoxicity, particularly in older adults.
  • Despite advances, cures for PNSL remain rare, necessitating improved therapeutic strategies.

Purpose of the Study:

  • To review current treatment standards for primary nervous system lymphoma.
  • To highlight the shift towards methotrexate-based chemotherapy as the primary treatment modality.
  • To discuss ongoing research into novel chemotherapeutic agents and treatment strategies for PNSL.

Main Methods:

  • Review of current literature and treatment guidelines for primary nervous system lymphoma.

Related Experiment Videos

  • Analysis of treatment outcomes associated with whole brain radiation therapy and methotrexate-based chemotherapy.
  • Discussion of emerging research on novel agents and therapeutic approaches, including intrathecal chemotherapy and blood-brain barrier disruption.

    • Main Results:

    • Methotrexate-based chemotherapy is now the standard of care for newly diagnosed PNSL.
    • Whole brain radiation therapy, while previously standard, is associated with high relapse rates and late neurotoxicity.
    • Identifying agents that effectively penetrate the blood-brain barrier and possess antilymphoma activity is a key research focus.

    Conclusions:

    • Current treatment paradigms for PNSL, while improved, rarely result in complete cures.
    • Further research is crucial to identify more effective chemotherapeutic agents and optimize treatment protocols.
    • Referral to specialized cancer centers for access to clinical trials is recommended for optimal patient management.